Next Biomedical seeks IPO…knocks on global GI mkt
By Hwang, Byung-woo | translator Kang, Shin-Kook
24.08.02 05:35:43
가나다라
0
Signed a global licensing agreement with Medtronic…generates sales in the US and Europe
CEO Don-Haeng Lee develops a GI endoscopic hemostasis system based on his professor background
Next Biomedical will seek KOSDAQ listing in August based on its achievements in the GI field.
The company has been collaborating with the global company Medtronic to expand into the endoscopic hemostatic agent market with its flagship product. Based on the revenue growth, the company plans to establish the drug as a standard-of-care in the global market.
▲Don-Haeng Lee, CEO of Next Biomedical, is making a presentation
Established in 2014, Next Biomedical is an innovative bio-solution company that develops therapeutic materials based on its polymer and drug delivery system technologies.
Its main products include an endoscopic hemostatic powder (Nexpowder), an endovascular embolization microsphere (Nexsphere), and an arthritis
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)